An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations.
Adjusted comparison
Amivantamab
Exon 20 insertion mutations
Non-small cell lung cancer
Real-world clinical practice
Journal
Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
received:
05
10
2022
accepted:
12
12
2022
pubmed:
19
1
2023
medline:
9
3
2023
entrez:
18
1
2023
Statut:
ppublish
Résumé
Patients with advanced, epidermal growth factor receptor (EGFR)-mutated, non-small cell lung cancer (NSCLC) with Exon 20 insertion mutations (Exon20ins) have poor prognoses, exacerbated by a previous lack of specific treatment guidelines and unmet need for targeted therapies. Amivantamab, an EGFR and MET bispecific antibody, demonstrated efficacy and tolerability in patients with advanced EGFR-mutated NSCLC with Exon20ins following platinum-based therapy in CHRYSALIS (NCT02609776; Cohort D+). Since CHRYSALIS was single-arm, individual patient data (IPD)-based adjusted analyses versus similar patients in real-world clinical practice (RWCP) were conducted to generate comparative evidence. RWCP cohorts were derived from seven European and US real-world sources, comprising patients fulfilling CHRYSALIS Cohort D+ eligibility criteria. Amivantamab was compared with a basket of RWCP treatments. Differences in prognostic characteristics were adjusted for using inverse probability weighting (IPW; average treatment effect among the treated [ATT]). Balance between cohorts was assessed using standardized mean differences (SMDs). Overall response rate (ORR; investigator- [INV] and independent review committee-assessed [IRC]), overall survival (OS), progression-free survival (PFS; INV and IRC) and time-to-next treatment (TTNT) were compared. Binary and time-to-event endpoints were analyzed using weighted logistic regression and proportional hazards regression, respectively. Pre-adjustment, baseline characteristics were comparable between cohorts. IPW ATT-adjustment improved comparability, giving closely matched characteristics. ORR (INV) was 36.8% for amivantamab versus 17.0% for the adjusted EU + US cohort (response rate ratio [RR]: 2.16). Median OS, PFS (INV) and TTNT were 22.77 versus 12.52 months (hazard ratio [HR]: 0.47; p < 0.0001), 6.93 versus 4.17 months (HR: 0.55; p < 0.0001) and 12.42 versus 5.36 months (HR: 0.44; p < 0.0001) for amivantamab versus the adjusted EU + US cohort, respectively. Results were consistent versus EU- and US-only cohorts, and when using IRC assessment. Adjusted comparisons demonstrated significantly improved outcomes for amivantamab versus RWCP, highlighting the value of amivantamab in addressing unmet need in patients with advanced EGFR Exon20ins NSCLC following platinum-based therapy. CHRYSALIS: NCT02609776.
Identifiants
pubmed: 36652175
doi: 10.1007/s12325-022-02408-7
pii: 10.1007/s12325-022-02408-7
pmc: PMC9988783
doi:
Substances chimiques
amivantamab-vmjw
0
Antineoplastic Agents
0
ErbB Receptors
EC 2.7.10.1
Protein Kinase Inhibitors
0
Banques de données
ClinicalTrials.gov
['NCT02609776']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
1187-1203Informations de copyright
© 2023. The Author(s).
Références
Vyse S, Huang PH. Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer. Signal Transduct Target Ther. 2019;4:5.
doi: 10.1038/s41392-019-0038-9
pubmed: 30854234
pmcid: 6405763
Van Sanden S, Murton M, Bobrowska A, et al. Prevalence of epidermal growth factor receptor exon 20 insertion mutations in non-small-cell lung cancer in Europe: a pragmatic literature review and meta-analysis. Target Oncol. 2022;17:153–66.
doi: 10.1007/s11523-022-00868-z
pubmed: 35226283
pmcid: 8995294
Zhang YL, Yuan JQ, Wang KF, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016;7:78985–93.
doi: 10.18632/oncotarget.12587
pubmed: 27738317
pmcid: 5346692
Burnett H, Emich H, Carroll C, et al. Epidemiological and clinical burden of EGFR exon 20 insertion in advanced non-small cell lung cancer: a systematic literature review. PLoS ONE. 2021;16: e0247620.
doi: 10.1371/journal.pone.0247620
pubmed: 33684140
pmcid: 7939356
Chouaid C, Filleron T, Debieuvre D, et al. A real-world study of patients with advanced non-squamous non-small cell lung cancer with EGFR exon 20 insertion: clinical characteristics and outcomes. Target Oncol. 2021;16:801–11.
doi: 10.1007/s11523-021-00848-9
pubmed: 34661827
Bazhenova L, Minchom A, Viteri S, et al. Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations. Lung Cancer. 2021;162:154–61.
doi: 10.1016/j.lungcan.2021.10.020
pubmed: 34818606
Oxnard GR, Lo PC, Nishino M, et al. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J Thorac Oncol. 2013;8:179–84.
doi: 10.1097/JTO.0b013e3182779d18
pubmed: 23328547
pmcid: 3549533
Girard N, Bazhenova L, Minchom A, et al. Comparative clinical outcomes for patients with NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations. J Thorac Oncol. 2021;16:S145–6.
doi: 10.1016/j.jtho.2021.01.228
National Comprehensive Cancer Network. Clinical practice guidelines in oncology: non-small cell lung cancer. Version 5. 2022. Available at: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1450 . Last accessed: Nov 2022.
Leitlinienprogramm Onkologie. S3-Leitlinie Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. 2022. Available at: https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/LL_Lungenkarzinom_Langversion_2.01.pdf . Last accessed: July 2022.
Park K, Haura EB, Leighl NB, et al. Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study. J Clin Oncol. 2021;39:3391–402.
doi: 10.1200/JCO.21.00662
pubmed: 34339292
pmcid: 8791812
European Medicines Agency (EMA). European Public Assessment Report: Rybrevant. Available at: https://www.ema.europa.eu/en/documents/product-information/rybrevant-epar-product-information_en.pdf . Last accessed: Nov 2022.
Medicines and Healthcare products Regulatory Agency (MHRA). Rybrevant 50 mg/ml concentrate for solution for infusion SmPC. 2021. Available at: https://mhraproducts4853.blob.core.windows.net/docs/d25ead446a4a1bc2da9f3aa220b0ce8422247ba3 . Last accessed: July 2022.
U.S. Food and Drug Administration. Prescribing information: ybrevant (amivantamab-vmjw) injection, for intravenous use. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761210s000lbl.pdf . Last accessed: July 2022.
ClinicalTrails.gov. A study of combination amivantamab and carboplatin-pemetrexed therapy, compared with carboplatin-pemetrexed, in participants with advanced or metastatic non-small cell lung cancer characterized by epidermal growth factor receptor (EGFR) exon 20 insertions (PAPILLON). Available at: https://clinicaltrials.gov/ct2/show/NCT04538664 . Last accessed: July 2022.
Hou J, Li H, Ma S, et al. EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives. Biomark Res. 2022;10:21.
doi: 10.1186/s40364-022-00372-6
pubmed: 35418149
pmcid: 9008900
Herbert A, Wijlaars L, Zylbersztejn A, et al. Data resource profile: hospital episode statistics admitted patient care (HES APC). Int J Epidemiol. 2017;46:1093–1093i.
doi: 10.1093/ije/dyx015
pubmed: 28338941
pmcid: 5837677
Bright CJ, Lawton S, Benson S, et al. Data resource profile: the systemic anti-cancer therapy (SACT) dataset. Int J Epidemiol. 2020;49:15–15l.
doi: 10.1093/ije/dyz137
pubmed: 31340008
Henson KE, Elliss-Brookes L, Coupland VH, et al. Data resource profile: national cancer registration dataset in England. Int J Epidemiol. 2020;49:16–16h.
doi: 10.1093/ije/dyz076
pubmed: 31120104
Danaei G, Rodríguez LAG, Cantero OF, et al. Observational data for comparative effectiveness research: an emulation of randomised trials of statins and primary prevention of coronary heart disease. Stat Methods Med Res. 2011;22:70–96.
doi: 10.1177/0962280211403603
pubmed: 22016461
pmcid: 3613145
Hernán MA, Alonso A, Logan R, et al. Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. Epidemiology. 2008;19:766–79.
doi: 10.1097/EDE.0b013e3181875e61
pubmed: 18854702
pmcid: 3731075
Hernán MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol. 2016;183:758–64.
doi: 10.1093/aje/kwv254
pubmed: 26994063
pmcid: 4832051
Backenroth D. How to choose a time zero for patients in external control arms. Pharm Stat. 2021;20:783–92.
doi: 10.1002/pst.2107
pubmed: 33655598
Nicolas Girard, Lyudmila Bazhenova, Anna Minchom, et al. Comparative clinical outcomes for patients with NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations. In: Presented at the IASLC 2020 World Conference on Lung Cancer. 2021.
Remon J, Hendriks LEL, Cardona AF et al. EGFR exon 20 insertions in advanced non-small cell lung cancer: a new history begins. Cancer Treat Rev. 2020;90:102105.
doi: 10.1016/j.ctrv.2020.102105
pubmed: 32979839
Choudhury NJ, Schoenfeld AJ, Flynn J, et al. Response to standard therapies and comprehensive genomic analysis for patients with lung adenocarcinoma with EGFR exon 20 insertions. Clin Cancer Res. 2021;27:2920–7.
doi: 10.1158/1078-0432.CCR-20-4650
pubmed: 33685865
pmcid: 8127357
Vasconcelos P, Gergis C, Viray H et al. EGFR-A763_Y764insFQEA is a unique exon 20 insertion mutation that displays sensitivity to approved and in-development lung cancer EGFR tyrosine kinase inhibitors. JTO Clin Res Rep. 2020;1(3):100051.
pubmed: 34104899
pmcid: 8183979
Coleman N, Woolf D, Welsh L, et al. EGFR exon 20 insertion (A763_Y764insFQEA) mutant NSCLC is not identified by Roche Cobas version 2 tissue testing but has durable intracranial and extracranial response to osimertinib. J Thorac Oncol. 2020;15:e162–5.
doi: 10.1016/j.jtho.2020.05.006
pubmed: 32981603
Gergis C, Rangachari D, Fujii M, et al. EGFR-A763_Y764insFQEA: a unique exon 20 insertion mutation that displays sensitivity to all classes of approved lung cancer EGFR tyrosine kinase inhibitors. J Clin Oncol. 2019;37:e20593–e20593.
doi: 10.1200/JCO.2019.37.15_suppl.e20593
Minchom A, Viteri S, Bazhenova L et al. Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy. Lung Cancer. 2022;168:74–82.
doi: 10.1016/j.lungcan.2022.03.005
pubmed: 35597172
Mountzios G, Planchard D, Metro G et al. Molecular epidemiology and treatment patterns of patients with EGFR exon 20-mutant NSCLC in the precision oncology era: the European EXOTIC registry. JTO Clin Res Rep. 2022:100433. https://doi.org/10.1016/j.jtocrr.2022.100433